Re-evaluating the predictive roles of metabolic complications and clinical outcome according to eGFR levels -a four-years prospective cohort study in Taiwan

详细信息    查看全文

• 作者：I-Wen Wu (1) (2)
  Kuang-Hung Hsu (3)
  Chin-Chan Lee (1) (2)
  Chiao-Yin Sun (1) (2)
  Heng-Jung Hsu (1) (2)
  Ming-Jui Hung (2) (4)
  Mai-Szu Wu (1) (5) (6)
  
• 关键词：Anemia ; Chronic kidney disease ; Death ; Hyperphosphatemia ; Hypoalbuminemia ; Metabolic complications ; Renal progression
• 刊名：BMC Nephrology
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：14
• 期：1
• 全文大小：296KB
• 参考文献：1. De Nicola L, Chiodini P, Zoccali C, Borrelli S, Cianciaruso B, Di Iorio B, Santoro D, Giancaspro V, Abaterusso C, Gallo C: Prognosis of CKD patients receiving outpatient nephrology care in Italy. / Clin J Am Soc Nephrol 2011,6(10):2421-428. CrossRef
  2. Hoefield RA, Kalra PA, Baker P, Lane B, New JP, O’Donoghue DJ, Foley RN, Middleton RJ: Factors associated with kidney disease progression and mortality in a referred CKD population. / Am J Kidney Dis 2010,56(6):1072-081. CrossRef
  3. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU: The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. / Kidney Int 2011,80(1):17-8. CrossRef
  4. De Nicola L, Minutolo R, Chiodini P, Zamboli P, Cianciaruso B, Nappi F, Signoriello S, Conte G, Zoccali C, Group S-TCS: Prevalence and prognosis of mild anemia in non-dialysis chronic kidney disease: a prospective cohort study in outpatient renal clinics. / Am J Nephrol 2010,32(6):533-40. CrossRef
  5. Bellasi A, Mandreoli M, Baldrati L, Corradini M, Di Nicolo P, Malmusi G, Santoro A: Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction. / Clin J Am Soc Nephrol 2011,6(4):883-91. CrossRef
  6. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC: The frequency of hyperkalemia and its significance in chronic kidney disease. / Arch Intern Med 2009,169(12):1156-162. CrossRef
  7. Menon V, Tighiouart H, Vaughn NS, Beck GJ, Kusek JW, Collins AJ, Greene T, Sarnak MJ: Serum bicarbonate and long-term outcomes in CKD. / Am J Kidney Dis 2010,56(5):907-14. CrossRef
  8. Bellomo G, Venanzi S, Verdura C, Saronio P, Esposito A, Timio M: Association of uric acid with change in kidney function in healthy normotensive individuals. / Am J Kidney Dis 2010,56(2):264-72. CrossRef
  9. Bash LD, Erlinger TP, Coresh J, Marsh-Manzi J, Folsom AR, Astor BC: Inflammation, hemostasis, and the risk of kidney function decline in the atherosclerosis risk in communities (ARIC) study. / Am J Kidney Dis 2009,53(4):596-05. CrossRef
  10. Wu IW, Wang SY, Hsu KH, Lee CC, Sun CY, Tsai CJ, Wu MS: Multidisciplinary predialysis education decreases the incidence of dialysis and reduces mortality–a controlled cohort study based on the NKF/DOQI guidelines. / Nephrol Dial Transplant 2009, 24:3426-433. CrossRef
  11. KDOQI: Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. / Am J Kidney Dis 2006,47(5 Suppl 3):S11-S145.
  12. KDIGO: Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). / Kidney Int Suppl 2009, (113):S1-S130.
  13. Nagelkerke NJD: A note on a general definition of the coefficient of determination. / Biometrika 1991, 78:691-92. CrossRef
  14. Menon V, Greene T, Wang X, Pereira AA, Marcovina SM, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ: C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. / Kidney Int 2005,68(2):766-72.
  15. K/DOQI, National Kidney Foundation: Clinical practice guidelines for nutrition in chronic renal failure. / Am J Kidney Dis 2000,35(6 Suppl 2):S1-S140.
  16. Barbour SJ, Er L, Djurdjev O, Karim MA, Levin A: The prevalence of hematologic and metabolic abnormalities during chronic kidney disease stages in different ethnic groups. / Kidney Int 2008,74(1):108-14. CrossRef
  17. Moranne O, Froissart M, Rossert J, Gauci C, Boffa JJ, Haymann JP, M’Rad MB, Jacquot C, Houillier P, Stengel B: Timing of onset of CKD-related metabolic complications. / J Am Soc Nephrol 2009,20(1):164-71. CrossRef
  18. Inker LA, Coresh J, Levey AS, Tonelli M, Muntner P: Estimated GFR, albuminuria, and complications of chronic kidney disease. / J Am Soc Nephrol 2011,22(12):2322-331. CrossRef
  19. O’Seaghdha CM, Parekh RS, Hwang SJ, Li M, Kottgen A, Coresh J, Yang Q, Fox CS, Kao WH: The MYH9/APOL1 region and chronic kidney disease in european-americans. / Hum Mol Genet 2011,20(12):2450-456. CrossRef
  20. Ibrahim HN, Wang C, Ishani A, Collins AJ, Foley RN: Screening for chronic kidney disease complications in US adults: racial implications of a single GFR threshold. / Clin J Am Soc Nephrol 2008,3(6):1792-799. CrossRef
  21. Barbour SJ, Er L, Djurdjev O, Karim M, Levin A: Differences in progression of CKD and mortality amongst caucasian, oriental asian and south asian CKD patients. / Nephrol Dial Transplant 2010,25(11):3663-672. CrossRef
  22. Kovesdy CP, Kuchmak O, Lu JL, Kalantar-Zadeh K: Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD. / Am J Kidney Dis 2010,56(5):842-51. CrossRef
  23. Moorthi RN, Kandula P, Moe SM: Optimal vitamin D, calcitriol, and vitamin D analog replacement in chronic kidney disease: to D or not to D: that is the question. / Curr Opin Nephrol Hypertens 2011,20(4):354-59. CrossRef
  24. Boudville NC, Djurdjev O, Macdougall IC, de Francisco AL, Deray G, Besarab A, Stevens PE, Walker RG, Urena P, Inigo P: Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality. / Clin J Am Soc Nephrol 2009,4(7):1176-182. CrossRef
  25. Turner JM, Bauer C, Abramowitz MK, Melamed ML, Hostetter TH: Treatment of chronic kidney disease. / Kidney Int 2012,81(4):351-62. CrossRef
  26. Hsu CY, Propert K, Xie D, Hamm L, He J, Miller E, Ojo A, Shlipak M, Teal V, Townsend R: Measured GFR does not outperform estimated GFR in predicting CKD-related complications. / J Am Soc Nephrol 2011,22(10):1931-937. CrossRef
  27. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2369/14/92/prepub
  
• 作者单位：I-Wen Wu (1) (2)
  Kuang-Hung Hsu (3)
  Chin-Chan Lee (1) (2)
  Chiao-Yin Sun (1) (2)
  Heng-Jung Hsu (1) (2)
  Ming-Jui Hung (2) (4)
  Mai-Szu Wu (1) (5) (6)
  
  1. Department of Nephrology, Chang Gung Memorial Hospital, Keelung, Taiwan
  2. College of Medicine, Keelung, Taiwan
  3. Department of Health Care Management, Laboratory for Epidemiology, Healthy Aging Research Center, Chang Gung University, Taoyuan, Taiwan
  4. Department of Cardiology, Chang Gung Memorial Hospital, Keelung, Taiwan
  5. Division of Nephrology, Taipei Medical University Hospital, 252, Wu Hsiung Street, Taipei, 11031, Taiwan
  6. School of Medicine, Taipei Medical University, Taipei, Taiwan
  

文摘

Background Metabolic complications are associated with clinical outcomes in patients with chronic kidney disease (CKD). These outcomes differ among patients according to the different stages of disease. The prevalence and association of type and number of metabolic complications with renal progression and death in patients having different eGFR levels has high clinical value, but this fact has been rarely evaluated in prospective studies. Methods We prospectively followed a cohort of 1157 CKD patients from 2006 to death or until 2010, and evaluated the prevalence of CKD-related complications and their association with renal progression (defined as a decline in eGFR by > 50% from baseline, or end-stage renal disease requiring dialysis) and death in patients with eGFRs above and below 45 mL/min/1.73 m2 using Cox-proportional hazard models. Results The estimated rate (per 100 patient-years) of renal progression and death were 11.9 and 4.9, respectively. The eGFR thresholds determined by ROC analysis with a sensitivity of 90% for any metabolic complication were 60.8 mL/min/1.73 m2 and 74.3 mL/min/1.73 m2 using the MDRD and CKD Epidemiology Collaboration equations, respectively. CKD-related complications associated with renal progression in patients having eGFR < 45 mL/min/1.73 m2 were hyperphosphatemia, anemia, microinflammation and hypoalbuminemia. Those CKD-related complications associated with death were hypoalbuminemia and hyperuricemia. Hypoalbuminemia predicted renal progression, and, hypoalbuminemia and microinflammation predicted death in patients with eGFR ?45 mL/min/1.73 m2. The number of complications (?3) independently predicted both endpoints in patients with eGFR < 45 mL/min/1.73 m2. Conclusions Hypoalbuminemia was a unique and strong predictor of renal progression and all-cause mortality in CKD patients, independent of their demographic characteristics, traditional risk factors, renal function severity, the presence of cardiovascular disease and other metabolic abnormalities. Most other metabolic complications and the number of complications (?) were associated with the clinical outcomes of patients with eGFR < 45 mL/min/1.73 m2 rather than in those with higher eGFRs. The findings from the present study offer a novel insight into the association between metabolic complications and patient outcomes and may help to refine risk stratification according to disease stage.